Customize your JAMA Network experience by selecting one or more topics from the list below.
In the Viewpoint entitled “The Orphan Drug Act Revisited,”1 published in the March 5, 2019, issue of JAMA, there was incorrect wording used to describe the Orphan Drug Act. In all instances, “patent protection” and “patent exclusivity” should have read “market exclusivity.” The sentences should have read as follows: “To promote the development of orphan drug therapies, the ODA provided companies that engaged in research for drugs with populations of fewer that 200 000 patients with tax incentives, research substudies, and extended market exclusivity”; “These impressive revenues do not consider the substantial financial incentives companies receive in fee waivers and extended market exclusivity”; and “Another possibility would be to enact price regulations for orphan drugs after their extended market exclusivity expires, if no generic competition has arisen.” This article was corrected online.
Incorrect Description of Drug Act. JAMA. 2019;322(5):469. doi:10.1001/jama.2019.10338
Coronavirus Resource Center
Create a personal account or sign in to: